Pulsed field ablation: a promise that came true

Area of Science:

• Cardiovascular medicine
• Electrophysiology
• Medical device technology

Background:

• Pulsed field ablation (PFA) is a nonthermal energy source utilizing electroporation for cell membrane disruption.
• PFA demonstrates selective myocardial tissue necrosis, positioning it as a potential 'perfect' energy source for cardiac ablation.
• Current research focuses on PFA platforms in clinical development for treating cardiac arrhythmias.

Purpose of the Study:

• To review the current status and clinical development of pulsed field ablation platforms.
• To highlight the safety and efficacy of PFA in treating cardiac arrhythmias, particularly atrial fibrillation.
• To discuss the expanding applications of PFA, including ventricular arrhythmias.

Main Methods:

• Review of first-in-human clinical series data for various PFA platforms.
• Analysis of acute safety and efficacy outcomes, including complication rates.
• Evaluation of 1-year clinical follow-up data for pulmonary vein isolation.

Main Results:

• First-in-human studies for PFA in atrial fibrillation ablation are complete, with published data for multiple platforms.
• Acute safety outcomes are comparable across platforms, showing significantly lower rates of esophageal injury, pulmonary vein stenosis, and phrenic nerve palsy than thermal methods.
• Satisfactory 1-year clinical follow-up data exist for one platform, with pending reports for others. Research is advancing towards focal catheter development for ventricular arrhythmias.

Conclusions:

• Pulsed field ablation demonstrates a favorable safety profile and efficacy for cardiac ablation procedures.
• The accumulating evidence supports PFA as a transformative technology in managing cardiac arrhythmias.
• Ongoing development in PFA technology, including focal catheters, promises broader applications in electrophysiology.